APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Antitumor API

Compare research editions
View pricing & licenses

Selected research

Industry Research

Antitumor API Industry Research Report 2026

Report ID 173226010526 December 2025143 pages

Choose your research edition.

Industry ResearchAntitumor API Industry Research Report 2026143 pages · $2,950 USDIndustry Growth & TrendsGlobal Antitumor API Industry Growth and Trends Forecast to 2032122 pages · $3,450 USDMarket StructureGlobal Antitumor API Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032193 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Antitumor API Market Outlook and Growth Opportunities 2026217 pages · $4,250 USDMarket Analysis & ForecastGlobal Antitumor API Market Analysis and Forecast 2026-2032215 pages · $4,950 USD

Market perspective

The global Antitumor API market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.

The North America market for Antitumor API is forecast to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.

The Europe market for Antitumor API is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.

Read the full market overview

The Asia Pacific market for Antitumor API is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.

Leading global manufacturers of Antitumor API include , among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report quantifies the global Antitumor API market in revenue (US$ million) and, where applicable, sales volume (kg), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.

It standardizes definitions of types and applications, harmonizes vendor attribution, and presents comparable time series by company, type, application, and region/country, including indicative price bands (US$/kg) and concentration ratios (CR5/CR10).

The outputs are intended to support strategy development, budgeting, and performance benchmarking for manufacturers, new entrants, channel partners, and investors; the report also reviews technology shifts and notable product introductions relevant to Antitumor API.

Key Companies & Market Share Insights

This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.

Antitumor API Market by Company

Teva Pharmaceutical

Qilu Pharmaceutial

Zhejiang Xianju Junye Pharmaceutical

Hengrui

Hisun

Suanfarma

Sterling

Shivalik Rasayan

Shilpa Medicare

Sarv Biolabs

Piramal Pharma

Olon

Mac-Chem

Kekulepharma

Johnson Matthey

Hetero

Glenmark Life Sciences

Fresenius Kabi

Dr. Reddy’s Laboratories

Concord Biotech

Cipla

Biocon

Bachem

Aurisco Pharmaceutical

Aspen

Aenova

Antitumor API Segment by Type

Plant Alkaloids

Alkylating Agents

Antimetabolites

Others

Antitumor API Segment by Application

Injection

Oral Medicine

Antitumor API Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Antitumor API market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Antitumor API and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market

5. This report helps stakeholders to gain insights into which regions to target globally

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Antitumor API.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Research objectives, research methods, data sources, data cross-validation;

Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 3: Detailed analysis of Antitumor API manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.

Chapter 5: Production/output, value of Antitumor API by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.

Chapter 6: Consumption of Antitumor API in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.

Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 11: The main points and conclusions of the report.

More report detail

Tables and figures
List of Tables Table 1. Secondary Sources Table 2. Primary Sources Table 3. Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 4. Market Value Comparison by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 5. Global Antitumor API Production by Manufacturers (kg) & (2021-2026) Table 6. Global Antitumor API Production Market Share by Manufacturers Table 7. Global Antitumor API Production Value by Manufacturers (US$ Million) & (2021-2026) Table 8. Global Antitumor API Production Value Market Share by Manufacturers (2021-2026) Table 9. Global Antitumor API Average Price (USD/kg) of Manufacturers (2021-2026) Table 10. Global Antitumor API Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global Antitumor API Key Manufacturers, Manufacturing Sites & Headquarters Table 12. Global Antitumor API Manufacturers, Product Type & Application Table 13. Global Antitumor API Manufacturers Established Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global Antitumor API by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Production Value of 2025) Table 16. Manufacturers Mergers & Acquisitions, Expansion Plans Table 17. Teva Pharmaceutical Company Information Table 18. Teva Pharmaceutical Business Overview Table 19. Teva Pharmaceutical Antitumor API Production (kg), Value (US$ Million), Price (USD/kg) and Gross Margin (2021-2026) Table 20. Teva Pharmaceutical Antitumor API Product Portfolio Table 21. Teva Pharmaceutical Recent Development Table 22. Qilu Pharmaceutial Company Information Table 23. Qilu Pharmaceutial Business Overview Table 24. Qilu Pharmaceutial Antitumor API Production (kg), Value (US$ Million), Price (USD/kg) and Gross Margin (2021-2026) Table 25. Qilu Pharmaceutial Antitumor API Product Portfolio Table 26. Qilu Pharmaceutial Recent Development Table 27. Zhejiang Xianju Junye Pharmaceutical Company Information Table 28. Zhejiang Xianju Junye Pharmaceutical Business Overview Table 29. Zhejiang Xianju Junye Pharmaceutical Antitumor API Production (kg), Value (US$ Million), Price (USD/kg) and Gross Margin (2021-2026) Table 30. Zhejiang Xianju Junye Pharmaceutical Antitumor API Product Portfolio Table 31. Zhejiang Xianju Junye Pharmaceutical Recent Development Table 32. Hengrui Company Information Table 33. Hengrui Business Overview Table 34. Hengrui Antitumor API Production (kg), Value (US$ Million), Price (USD/kg) and Gross Margin (2021-2026) Table 35. Hengrui Antitumor API Product Portfolio Table 36. Hengrui Recent Development Table 37. Hisun Company Information Table 38. Hisun Business Overview Table 39. Hisun Antitumor API Production (kg), Value (US$ Million), Price (USD/kg) and Gross Margin (2021-2026) Table 40. Hisun Antitumor API Product Portfolio Table 41. Hisun Recent Development Table 42. Suanfarma Company Information Table 43. Suanfarma Business Overview Table 44. Suanfarma Antitumor API Production (kg), Value (US$ Million), Price (USD/kg) and Gross Margin (2021-2026) Table 45. Suanfarma Antitumor API Product Portfolio Table 46. Suanfarma Recent Development Table 47. Sterling Company Information Table 48. Sterling Business Overview Table 49. Sterling Antitumor API Production (kg), Value (US$ Million), Price (USD/kg) and Gross Margin (2021-2026) Table 50. Sterling Antitumor API Product Portfolio Table 51. Sterling Recent Development Table 52. Shivalik Rasayan Company Information Table 53. Shivalik Rasayan Business Overview Table 54. Shivalik Rasayan Antitumor API Production (kg), Value (US$ Million), Price (USD/kg) and Gross Margin (2021-2026) Table 55. Shivalik Rasayan Antitumor API Product Portfolio Table 56. Shivalik Rasayan Recent Development Table 57. Shilpa Medicare Company Information Table 58. Shilpa Medicare Business Overview Table 59. Shilpa Medicare Antitumor API Production (kg), Value (US$ Million), Price (USD/kg) and Gross Margin (2021-2026) Table 60. Shilpa Medicare Antitumor API Product Portfolio Table 61. Shilpa Medicare Recent Development Table 62. Sarv Biolabs Company Information Table 63. Sarv Biolabs Business Overview Table 64. Sarv Biolabs Antitumor API Production (kg), Value (US$ Million), Price (USD/kg) and Gross Margin (2021-2026) Table 65. Sarv Biolabs Antitumor API Product Portfolio Table 66. Sarv Biolabs Recent Development Table 67. Piramal Pharma Company Information Table 68. Piramal Pharma Business Overview Table 69. Piramal Pharma Antitumor API Production (kg), Value (US$ Million), Price (USD/kg) and Gross Margin (2021-2026) Table 70. Piramal Pharma Antitumor API Product Portfolio Table 71. Piramal Pharma Recent Development Table 72. Olon Company Information Table 73. Olon Business Overview Table 74. Olon Antitumor API Production (kg), Value (US$ Million), Price (USD/kg) and Gross Margin (2021-2026) Table 75. Olon Antitumor API Product Portfolio Table 76. Olon Recent Development Table 77. Mac-Chem Company Information Table 78. Mac-Chem Business Overview Table 79. Mac-Chem Antitumor API Production (kg), Value (US$ Million), Price (USD/kg) and Gross Margin (2021-2026) Table 80. Mac-Chem Antitumor API Product Portfolio Table 81. Mac-Chem Recent Development Table 82. Kekulepharma Company Information Table 83. Kekulepharma Business Overview Table 84. Kekulepharma Antitumor API Production (kg), Value (US$ Million), Price (USD/kg) and Gross Margin (2021-2026) Table 85. Kekulepharma Antitumor API Product Portfolio Table 86. Kekulepharma Recent Development Table 87. Johnson Matthey Company Information Table 88. Johnson Matthey Business Overview Table 89. Johnson Matthey Antitumor API Production (kg), Value (US$ Million), Price (USD/kg) and Gross Margin (2021-2026) Table 90. Johnson Matthey Antitumor API Product Portfolio Table 91. Johnson Matthey Recent Development Table 92. Hetero Company Information Table 93. Hetero Business Overview Table 94. Hetero Antitumor API Production (kg), Value (US$ Million), Price (USD/kg) and Gross Margin (2021-2026) Table 95. Hetero Antitumor API Product Portfolio Table 96. Hetero Recent Development Table 97. Glenmark Life Sciences Company Information Table 98. Glenmark Life Sciences Business Overview Table 99. Glenmark Life Sciences Antitumor API Production (kg), Value (US$ Million), Price (USD/kg) and Gross Margin (2021-2026) Table 100. Glenmark Life Sciences Antitumor API Product Portfolio Table 101. Glenmark Life Sciences Recent Development Table 102. Fresenius Kabi Company Information Table 103. Fresenius Kabi Business Overview Table 104. Fresenius Kabi Antitumor API Production (kg), Value (US$ Million), Price (USD/kg) and Gross Margin (2021-2026) Table 105. Fresenius Kabi Antitumor API Product Portfolio Table 106. Fresenius Kabi Recent Development Table 107. Dr. Reddy’s Laboratories Company Information Table 108. Dr. Reddy’s Laboratories Business Overview Table 109. Dr. Reddy’s Laboratories Antitumor API Production (kg), Value (US$ Million), Price (USD/kg) and Gross Margin (2021-2026) Table 110. Dr. Reddy’s Laboratories Antitumor API Product Portfolio Table 111. Dr. Reddy’s Laboratories Recent Development Table 112. Concord Biotech Company Information Table 113. Concord Biotech Business Overview Table 114. Concord Biotech Antitumor API Production (kg), Value (US$ Million), Price (USD/kg) and Gross Margin (2021-2026) Table 115. Concord Biotech Antitumor API Product Portfolio Table 116. Concord Biotech Recent Development Table 117. Cipla Company Information Table 118. Cipla Business Overview Table 119. Cipla Antitumor API Production (kg), Value (US$ Million), Price (USD/kg) and Gross Margin (2021-2026) Table 120. Cipla Antitumor API Product Portfolio Table 121. Cipla Recent Development Table 122. Biocon Company Information Table 123. Biocon Business Overview Table 124. Biocon Antitumor API Production (kg), Value (US$ Million), Price (USD/kg) and Gross Margin (2021-2026) Table 125. Biocon Antitumor API Product Portfolio Table 126. Biocon Recent Development Table 127. Bachem Company Information Table 128. Bachem Business Overview Table 129. Bachem Antitumor API Production (kg), Value (US$ Million), Price (USD/kg) and Gross Margin (2021-2026) Table 130. Bachem Antitumor API Product Portfolio Table 131. Bachem Recent Development Table 132. Aurisco Pharmaceutical Company Information Table 133. Aurisco Pharmaceutical Business Overview Table 134. Aurisco Pharmaceutical Antitumor API Production (kg), Value (US$ Million), Price (USD/kg) and Gross Margin (2021-2026) Table 135. Aurisco Pharmaceutical Antitumor API Product Portfolio Table 136. Aurisco Pharmaceutical Recent Development Table 137. Aspen Company Information Table 138. Aspen Business Overview Table 139. Aspen Antitumor API Production (kg), Value (US$ Million), Price (USD/kg) and Gross Margin (2021-2026) Table 140. Aspen Antitumor API Product Portfolio Table 141. Aspen Recent Development Table 142. Aenova Company Information Table 143. Aenova Business Overview Table 144. Aenova Antitumor API Production (kg), Value (US$ Million), Price (USD/kg) and Gross Margin (2021-2026) Table 145. Aenova Antitumor API Product Portfolio Table 146. Aenova Recent Development Table 147. Global Antitumor API Production Comparison by Region: 2021 VS 2025 VS 2032 (kg) Table 148. Global Antitumor API Production by Region (2021-2026) & (kg) Table 149. Global Antitumor API Production Market Share by Region (2021-2026) Table 150. Global Antitumor API Production Forecast by Region (2027-2032) & (kg) Table 151. Global Antitumor API Production Market Share Forecast by Region (2027-2032) Table 152. Global Antitumor API Production Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 153. Global Antitumor API Production Value by Region (2021-2026) & (US$ Million) Table 154. Global Antitumor API Production Value Market Share by Region (2021-2026) Table 155. Global Antitumor API Production Value Forecast by Region (2027-2032) & (US$ Million) Table 156. Global Antitumor API Market Average Price (USD/kg) by Region (2021-2026) Table 157. Global Antitumor API Market Average Price (USD/kg) by Region (2027-2032) Table 158. Global Antitumor API Consumption Comparison by Region: 2021 VS 2025 VS 2032 (kg) Table 159. Global Antitumor API Consumption by Region (2021-2026) & (kg) Table 160. Global Antitumor API Consumption Market Share by Region (2021-2026) Table 161. Global Antitumor API Forecasted Consumption by Region (2027-2032) & (kg) Table 162. Global Antitumor API Forecasted Consumption Market Share by Region (2027-2032) Table 163. North America Antitumor API Consumption Growth Rate by Country: 2021 VS 2025 VS 2032 (kg) Table 164. North America Antitumor API Consumption by Country (2021-2026) & (kg) Table 165. North America Antitumor API Consumption by Country (2027-2032) & (kg) Table 166. Europe Antitumor API Consumption Growth Rate by Country: 2021 VS 2025 VS 2032 (kg) Table 167. Europe Antitumor API Consumption by Country (2021-2026) & (kg) Table 168. Europe Antitumor API Consumption by Country (2027-2032) & (kg) Table 169. Asia Pacific Antitumor API Consumption Growth Rate by Country: 2021 VS 2025 VS 2032 (kg) Table 170. Asia Pacific Antitumor API Consumption by Country (2021-2026) & (kg) Table 171. Asia Pacific Antitumor API Consumption by Country (2027-2032) & (kg) Table 172. South America, Middle East & Africa Antitumor API Consumption Growth Rate by Country: 2021 VS 2025 VS 2032 (kg) Table 173. South America, Middle East & Africa Antitumor API Consumption by Country (2021-2026) & (kg) Table 174. South America, Middle East & Africa Antitumor API Consumption by Country (2027-2032) & (kg) Table 175. Global Antitumor API Production by Type (2021-2026) & (kg) Table 176. Global Antitumor API Production by Type (2027-2032) & (kg) Table 177. Global Antitumor API Production Market Share by Type (2021-2026) Table 178. Global Antitumor API Production Market Share by Type (2027-2032) Table 179. Global Antitumor API Production Value by Type (2021-2026) & (US$ Million) Table 180. Global Antitumor API Production Value by Type (2027-2032) & (US$ Million) Table 181. Global Antitumor API Production Value Market Share by Type (2021-2026) Table 182. Global Antitumor API Production Value Market Share by Type (2027-2032) Table 183. Global Antitumor API Price by Type (2021-2026) & (USD/kg) Table 184. Global Antitumor API Price by Type (2027-2032) & (USD/kg) Table 185. Global Antitumor API Production by Application (2021-2026) & (kg) Table 186. Global Antitumor API Production by Application (2027-2032) & (kg) Table 187. Global Antitumor API Production Market Share by Application (2021-2026) Table 188. Global Antitumor API Production Market Share by Application (2027-2032) Table 189. Global Antitumor API Production Value by Application (2021-2026) & (US$ Million) Table 190. Global Antitumor API Production Value by Application (2027-2032) & (US$ Million) Table 191. Global Antitumor API Production Value Market Share by Application (2021-2026) Table 192. Global Antitumor API Production Value Market Share by Application (2027-2032) Table 193. Global Antitumor API Price by Application (2021-2026) & (USD/kg) Table 194. Global Antitumor API Price by Application (2027-2032) & (USD/kg) Table 195. Key Raw Materials Table 196. Raw Materials Key Suppliers Table 197. Antitumor API Distributors List Table 198. Antitumor API Customers List Table 199. Antitumor API Industry Trends Table 200. Antitumor API Industry Drivers Table 201. Antitumor API Industry Restraints Table 202. Authors List of This Report List of Figures Figure 1. Research Methodology Figure 2. Research Process Figure 3. Key Executives Interviewed Figure 4. Antitumor API Product Image Figure 5. Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 6. Plant Alkaloids Product Image Figure 7. Alkylating Agents Product Image Figure 8. Antimetabolites Product Image Figure 9. Others Product Image Figure 10. Injection Product Image Figure 11. Oral Medicine Product Image Figure 12. Global Antitumor API Production Value (US$ Million), 2021 VS 2025 VS 2032 Figure 13. Global Antitumor API Production Value (2021-2032) & (US$ Million) Figure 14. Global Antitumor API Production Capacity (2021-2032) & (kg) Figure 15. Global Antitumor API Production (2021-2032) & (kg) Figure 16. Global Antitumor API Average Price (USD/kg) & (2021-2032) Figure 17. Global Antitumor API Key Manufacturers, Manufacturing Sites & Headquarters Figure 18. Global Top 5 and 10 Antitumor API Players Market Share by Production Value in 2025 Figure 19. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 20. Global Antitumor API Production Comparison by Region: 2021 VS 2025 VS 2032 (kg) Figure 21. Global Antitumor API Production Market Share by Region: 2021 VS 2025 VS 2032 Figure 22. Global Antitumor API Production Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 23. Global Antitumor API Production Value Market Share by Region: 2021 VS 2025 VS 2032 Figure 24. North America Antitumor API Production Value (US$ Million) Growth Rate (2021-2032) Figure 25. Europe Antitumor API Production Value (US$ Million) Growth Rate (2021-2032) Figure 26. China Antitumor API Production Value (US$ Million) Growth Rate (2021-2032) Figure 27. Japan Antitumor API Production Value (US$ Million) Growth Rate (2021-2032) Figure 28. Global Antitumor API Consumption Comparison by Region: 2021 VS 2025 VS 2032 (kg) Figure 29. Global Antitumor API Consumption Market Share by Region: 2021 VS 2025 VS 2032 Figure 30. North America Antitumor API Consumption and Growth Rate (2021-2032) & (kg) Figure 31. North America Antitumor API Consumption Market Share by Country (2021-2032) Figure 32. United States Antitumor API Consumption and Growth Rate (2021-2032) & (kg) Figure 33. United States Antitumor API Consumption and Growth Rate (2021-2032) & (kg) Figure 34. Canada Antitumor API Consumption and Growth Rate (2021-2032) & (kg) Figure 35. Mexico Antitumor API Consumption and Growth Rate (2021-2032) & (kg) Figure 36. Europe Antitumor API Consumption and Growth Rate (2021-2032) & (kg) Figure 37. Europe Antitumor API Consumption Market Share by Country (2021-2032) Figure 38. Germany Antitumor API Consumption and Growth Rate (2021-2032) & (kg) Figure 39. France Antitumor API Consumption and Growth Rate (2021-2032) & (kg) Figure 40. U.K. Antitumor API Consumption and Growth Rate (2021-2032) & (kg) Figure 41. Italy Antitumor API Consumption and Growth Rate (2021-2032) & (kg) Figure 42. Russia Antitumor API Consumption and Growth Rate (2021-2032) & (kg) Figure 43. Spain Antitumor API Consumption and Growth Rate (2021-2032) & (kg) Figure 44. Netherlands Antitumor API Consumption and Growth Rate (2021-2032) & (kg) Figure 45. Switzerland Antitumor API Consumption and Growth Rate (2021-2032) & (kg) Figure 46. Sweden Antitumor API Consumption and Growth Rate (2021-2032) & (kg) Figure 47. Poland Antitumor API Consumption and Growth Rate (2021-2032) & (kg) Figure 48. Asia Pacific Antitumor API Consumption and Growth Rate (2021-2032) & (kg) Figure 49. Asia Pacific Antitumor API Consumption Market Share by Country (2021-2032) Figure 50. China Antitumor API Consumption and Growth Rate (2021-2032) & (kg) Figure 51. Japan Antitumor API Consumption and Growth Rate (2021-2032) & (kg) Figure 52. South Korea Antitumor API Consumption and Growth Rate (2021-2032) & (kg) Figure 53. India Antitumor API Consumption and Growth Rate (2021-2032) & (kg) Figure 54. Australia Antitumor API Consumption and Growth Rate (2021-2032) & (kg) Figure 55. Taiwan Antitumor API Consumption and Growth Rate (2021-2032) & (kg) Figure 56. Southeast Asia Antitumor API Consumption and Growth Rate (2021-2032) & (kg) Figure 57. South America, Middle East & Africa Antitumor API Consumption and Growth Rate (2021-2032) & (kg) Figure 58. South America, Middle East & Africa Antitumor API Consumption Market Share by Country (2021-2032) Figure 59. Brazil Antitumor API Consumption and Growth Rate (2021-2032) & (kg) Figure 60. Argentina Antitumor API Consumption and Growth Rate (2021-2032) & (kg) Figure 61. Chile Antitumor API Consumption and Growth Rate (2021-2032) & (kg) Figure 62. Turkey Antitumor API Consumption and Growth Rate (2021-2032) & (kg) Figure 63. GCC Countries Antitumor API Consumption and Growth Rate (2021-2032) & (kg) Figure 64. Global Antitumor API Production Market Share by Type (2021-2032) Figure 65. Global Antitumor API Production Value Market Share by Type (2021-2032) Figure 66. Global Antitumor API Price (USD/kg) by Type (2021-2032) Figure 67. Global Antitumor API Production Market Share by Application (2021-2032) Figure 68. Global Antitumor API Production Value Market Share by Application (2021-2032) Figure 69. Global Antitumor API Price (USD/kg) by Application (2021-2032) Figure 70. Antitumor API Value Chain Figure 71. Antitumor API Production Mode & Process Figure 72. Direct Comparison with Distribution Share Figure 73. Distributors Profiles Figure 74. Antitumor API Industry Opportunities and Challenges

Scope & coverage.

Types
  • Plant Alkaloids
  • Alkylating Agents
  • Antimetabolites
  • Others
Applications
  • Injection
  • Oral Medicine
Companies covered
  • Teva Pharmaceutical
  • Qilu Pharmaceutial
  • Zhejiang Xianju Junye Pharmaceutical
  • Hengrui
  • Hisun
  • Suanfarma
  • Sterling
  • Shivalik Rasayan
  • Shilpa Medicare
  • Sarv Biolabs
  • Piramal Pharma
  • Olon
  • Mac-Chem
  • Kekulepharma
  • Johnson Matthey
  • Hetero
  • Glenmark Life Sciences
  • Fresenius Kabi
  • Dr. Reddy’s Laboratories
  • Concord Biotech
  • Cipla
  • Biocon
  • Bachem
  • Aurisco Pharmaceutical
  • Aspen
  • Aenova

Inside the report.

1 Preface
  1. 1.1 Scope of Report
  2. 1.2 Reasons for Doing This Study
  3. 1.3 Research Methodology
  4. 1.4 Research Process
  5. 1.5 Data Source
  6. 1.5.1 Secondary Sources
  7. 1.5.2 Primary Sources
2 Market Overview
  1. 2.1 Product Definition
  2. 2.2 Antitumor API by Type
  3. 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
  4. 2.2.2 Plant Alkaloids
  5. 2.2.3 Alkylating Agents
  6. 2.2.4 Antimetabolites
  7. 2.2.5 Others
  8. 2.3 Antitumor API by Application
  9. 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032) & (US$ Million)
  10. 2.3.2 Injection
  11. 2.3.3 Oral Medicine
  12. 2.4 Global Market Growth Prospects
  13. 2.4.1 Global Antitumor API Production Value Estimates and Forecasts (2021-2032)
  14. 2.4.2 Global Antitumor API Production Capacity Estimates and Forecasts (2021-2032)
  15. 2.4.3 Global Antitumor API Production Estimates and Forecasts (2021-2032)
  16. 2.4.4 Global Antitumor API Market Average Price (2021-2032)
3 Market Competitive Landscape by Manufacturers
  1. 3.1 Global Antitumor API Production by Manufacturers (2021-2026)
  2. 3.2 Global Antitumor API Production Value by Manufacturers (2021-2026)
  3. 3.3 Global Antitumor API Average Price by Manufacturers (2021-2026)
  4. 3.4 Global Antitumor API Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Antitumor API Key Manufacturers, Manufacturing Sites & Headquarters
  6. 3.6 Global Antitumor API Manufacturers, Product Type & Application
  7. 3.7 Global Antitumor API Manufacturers Established Date
  8. 3.8 Global Antitumor API Market CR5 and HHI
  9. 3.9 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
  1. 4.1 Teva Pharmaceutical
  2. 4.1.1 Teva Pharmaceutical Antitumor API Company Information
  3. 4.1.2 Teva Pharmaceutical Antitumor API Business Overview
  4. 4.1.3 Teva Pharmaceutical Antitumor API Production Capacity, Value and Gross Margin (2021-2026)
  5. 4.1.4 Teva Pharmaceutical Product Portfolio
  6. 4.1.5 Teva Pharmaceutical Recent Developments
  7. 4.2 Qilu Pharmaceutial
  8. 4.2.1 Qilu Pharmaceutial Antitumor API Company Information
  9. 4.2.2 Qilu Pharmaceutial Antitumor API Business Overview
  10. 4.2.3 Qilu Pharmaceutial Antitumor API Production Capacity, Value and Gross Margin (2021-2026)
  11. 4.2.4 Qilu Pharmaceutial Product Portfolio
  12. 4.2.5 Qilu Pharmaceutial Recent Developments
  13. 4.3 Zhejiang Xianju Junye Pharmaceutical
  14. 4.3.1 Zhejiang Xianju Junye Pharmaceutical Antitumor API Company Information
  15. 4.3.2 Zhejiang Xianju Junye Pharmaceutical Antitumor API Business Overview
  16. 4.3.3 Zhejiang Xianju Junye Pharmaceutical Antitumor API Production Capacity, Value and Gross Margin (2021-2026)
  17. 4.3.4 Zhejiang Xianju Junye Pharmaceutical Product Portfolio
  18. 4.3.5 Zhejiang Xianju Junye Pharmaceutical Recent Developments
  19. 4.4 Hengrui
  20. 4.4.1 Hengrui Antitumor API Company Information
  21. 4.4.2 Hengrui Antitumor API Business Overview
  22. 4.4.3 Hengrui Antitumor API Production Capacity, Value and Gross Margin (2021-2026)
  23. 4.4.4 Hengrui Product Portfolio
  24. 4.4.5 Hengrui Recent Developments
  25. 4.5 Hisun
  26. 4.5.1 Hisun Antitumor API Company Information
  27. 4.5.2 Hisun Antitumor API Business Overview
  28. 4.5.3 Hisun Antitumor API Production Capacity, Value and Gross Margin (2021-2026)
  29. 4.5.4 Hisun Product Portfolio
  30. 4.5.5 Hisun Recent Developments
  31. 4.6 Suanfarma
  32. 4.6.1 Suanfarma Antitumor API Company Information
  33. 4.6.2 Suanfarma Antitumor API Business Overview
  34. 4.6.3 Suanfarma Antitumor API Production Capacity, Value and Gross Margin (2021-2026)
  35. 4.6.4 Suanfarma Product Portfolio
  36. 4.6.5 Suanfarma Recent Developments
  37. 4.7 Sterling
  38. 4.7.1 Sterling Antitumor API Company Information
  39. 4.7.2 Sterling Antitumor API Business Overview
  40. 4.7.3 Sterling Antitumor API Production Capacity, Value and Gross Margin (2021-2026)
  41. 4.7.4 Sterling Product Portfolio
  42. 4.7.5 Sterling Recent Developments
  43. 4.8 Shivalik Rasayan
  44. 4.8.1 Shivalik Rasayan Antitumor API Company Information
  45. 4.8.2 Shivalik Rasayan Antitumor API Business Overview
  46. 4.8.3 Shivalik Rasayan Antitumor API Production Capacity, Value and Gross Margin (2021-2026)
  47. 4.8.4 Shivalik Rasayan Product Portfolio
  48. 4.8.5 Shivalik Rasayan Recent Developments
  49. 4.9 Shilpa Medicare
  50. 4.9.1 Shilpa Medicare Antitumor API Company Information
  51. 4.9.2 Shilpa Medicare Antitumor API Business Overview
  52. 4.9.3 Shilpa Medicare Antitumor API Production Capacity, Value and Gross Margin (2021-2026)
  53. 4.9.4 Shilpa Medicare Product Portfolio
  54. 4.9.5 Shilpa Medicare Recent Developments
  55. 4.10 Sarv Biolabs
  56. 4.10.1 Sarv Biolabs Antitumor API Company Information
  57. 4.10.2 Sarv Biolabs Antitumor API Business Overview
  58. 4.10.3 Sarv Biolabs Antitumor API Production Capacity, Value and Gross Margin (2021-2026)
  59. 4.10.4 Sarv Biolabs Product Portfolio
  60. 4.10.5 Sarv Biolabs Recent Developments
  61. 4.11 Piramal Pharma
  62. 4.11.1 Piramal Pharma Antitumor API Company Information
  63. 4.11.2 Piramal Pharma Antitumor API Business Overview
  64. 4.11.3 Piramal Pharma Antitumor API Production Capacity, Value and Gross Margin (2021-2026)
  65. 4.11.4 Piramal Pharma Product Portfolio
  66. 4.11.5 Piramal Pharma Recent Developments
  67. 4.12 Olon
  68. 4.12.1 Olon Antitumor API Company Information
  69. 4.12.2 Olon Antitumor API Business Overview
  70. 4.12.3 Olon Antitumor API Production Capacity, Value and Gross Margin (2021-2026)
  71. 4.12.4 Olon Product Portfolio
  72. 4.12.5 Olon Recent Developments
  73. 4.13 Mac-Chem
  74. 4.13.1 Mac-Chem Antitumor API Company Information
  75. 4.13.2 Mac-Chem Antitumor API Business Overview
  76. 4.13.3 Mac-Chem Antitumor API Production Capacity, Value and Gross Margin (2021-2026)
  77. 4.13.4 Mac-Chem Product Portfolio
  78. 4.13.5 Mac-Chem Recent Developments
  79. 4.14 Kekulepharma
  80. 4.14.1 Kekulepharma Antitumor API Company Information
  81. 4.14.2 Kekulepharma Antitumor API Business Overview
  82. 4.14.3 Kekulepharma Antitumor API Production Capacity, Value and Gross Margin (2021-2026)
  83. 4.14.4 Kekulepharma Product Portfolio
  84. 4.14.5 Kekulepharma Recent Developments
  85. 4.15 Johnson Matthey
  86. 4.15.1 Johnson Matthey Antitumor API Company Information
  87. 4.15.2 Johnson Matthey Antitumor API Business Overview
  88. 4.15.3 Johnson Matthey Antitumor API Production Capacity, Value and Gross Margin (2021-2026)
  89. 4.15.4 Johnson Matthey Product Portfolio
  90. 4.15.5 Johnson Matthey Recent Developments
  91. 4.16 Hetero
  92. 4.16.1 Hetero Antitumor API Company Information
  93. 4.16.2 Hetero Antitumor API Business Overview
  94. 4.16.3 Hetero Antitumor API Production Capacity, Value and Gross Margin (2021-2026)
  95. 4.16.4 Hetero Product Portfolio
  96. 4.16.5 Hetero Recent Developments
  97. 4.17 Glenmark Life Sciences
  98. 4.17.1 Glenmark Life Sciences Antitumor API Company Information
  99. 4.17.2 Glenmark Life Sciences Antitumor API Business Overview
  100. 4.17.3 Glenmark Life Sciences Antitumor API Production Capacity, Value and Gross Margin (2021-2026)
  101. 4.17.4 Glenmark Life Sciences Product Portfolio
  102. 4.17.5 Glenmark Life Sciences Recent Developments
  103. 4.18 Fresenius Kabi
  104. 4.18.1 Fresenius Kabi Antitumor API Company Information
  105. 4.18.2 Fresenius Kabi Antitumor API Business Overview
  106. 4.18.3 Fresenius Kabi Antitumor API Production Capacity, Value and Gross Margin (2021-2026)
  107. 4.18.4 Fresenius Kabi Product Portfolio
  108. 4.18.5 Fresenius Kabi Recent Developments
  109. 4.19 Dr. Reddy’s Laboratories
  110. 4.19.1 Dr. Reddy’s Laboratories Antitumor API Company Information
  111. 4.19.2 Dr. Reddy’s Laboratories Antitumor API Business Overview
  112. 4.19.3 Dr. Reddy’s Laboratories Antitumor API Production Capacity, Value and Gross Margin (2021-2026)
  113. 4.19.4 Dr. Reddy’s Laboratories Product Portfolio
  114. 4.19.5 Dr. Reddy’s Laboratories Recent Developments
  115. 4.20 Concord Biotech
  116. 4.20.1 Concord Biotech Antitumor API Company Information
  117. 4.20.2 Concord Biotech Antitumor API Business Overview
  118. 4.20.3 Concord Biotech Antitumor API Production Capacity, Value and Gross Margin (2021-2026)
  119. 4.20.4 Concord Biotech Product Portfolio
  120. 4.20.5 Concord Biotech Recent Developments
  121. 4.21 Cipla
  122. 4.21.1 Cipla Antitumor API Company Information
  123. 4.21.2 Cipla Antitumor API Business Overview
  124. 4.21.3 Cipla Antitumor API Production Capacity, Value and Gross Margin (2021-2026)
  125. 4.21.4 Cipla Product Portfolio
  126. 4.21.5 Cipla Recent Developments
  127. 4.22 Biocon
  128. 4.22.1 Biocon Antitumor API Company Information
  129. 4.22.2 Biocon Antitumor API Business Overview
  130. 4.22.3 Biocon Antitumor API Production Capacity, Value and Gross Margin (2021-2026)
  131. 4.22.4 Biocon Product Portfolio
  132. 4.22.5 Biocon Recent Developments
  133. 4.23 Bachem
  134. 4.23.1 Bachem Antitumor API Company Information
  135. 4.23.2 Bachem Antitumor API Business Overview
  136. 4.23.3 Bachem Antitumor API Production Capacity, Value and Gross Margin (2021-2026)
  137. 4.23.4 Bachem Product Portfolio
  138. 4.23.5 Bachem Recent Developments
  139. 4.24 Aurisco Pharmaceutical
  140. 4.24.1 Aurisco Pharmaceutical Antitumor API Company Information
  141. 4.24.2 Aurisco Pharmaceutical Antitumor API Business Overview
  142. 4.24.3 Aurisco Pharmaceutical Antitumor API Production Capacity, Value and Gross Margin (2021-2026)
  143. 4.24.4 Aurisco Pharmaceutical Product Portfolio
  144. 4.24.5 Aurisco Pharmaceutical Recent Developments
  145. 4.25 Aspen
  146. 4.25.1 Aspen Antitumor API Company Information
  147. 4.25.2 Aspen Antitumor API Business Overview
  148. 4.25.3 Aspen Antitumor API Production Capacity, Value and Gross Margin (2021-2026)
  149. 4.25.4 Aspen Product Portfolio
  150. 4.25.5 Aspen Recent Developments
  151. 4.26 Aenova
  152. 4.26.1 Aenova Antitumor API Company Information
  153. 4.26.2 Aenova Antitumor API Business Overview
  154. 4.26.3 Aenova Antitumor API Production Capacity, Value and Gross Margin (2021-2026)
  155. 4.26.4 Aenova Product Portfolio
  156. 4.26.5 Aenova Recent Developments
5 Global Antitumor API Production by Region
  1. 5.1 Global Antitumor API Production Estimates and Forecasts by Region: 2021 VS 2025 VS 2032
  2. 5.2 Global Antitumor API Production by Region: 2021-2032
  3. 5.2.1 Global Antitumor API Production by Region: 2021-2026
  4. 5.2.2 Global Antitumor API Production Forecast by Region (2027-2032)
  5. 5.3 Global Antitumor API Production Value Estimates and Forecasts by Region: 2021 VS 2025 VS 2032
  6. 5.4 Global Antitumor API Production Value by Region: 2021-2032
  7. 5.4.1 Global Antitumor API Production Value by Region: 2021-2026
  8. 5.4.2 Global Antitumor API Production Value Forecast by Region (2027-2032)
  9. 5.5 Global Antitumor API Market Price Analysis by Region (2021-2026)
  10. 5.6 Global Antitumor API Production and Value, YOY Growth
  11. 5.6.1 North America Antitumor API Production Value Estimates and Forecasts (2021-2032)
  12. 5.6.2 Europe Antitumor API Production Value Estimates and Forecasts (2021-2032)
  13. 5.6.3 China Antitumor API Production Value Estimates and Forecasts (2021-2032)
  14. 5.6.4 Japan Antitumor API Production Value Estimates and Forecasts (2021-2032)
6 Global Antitumor API Consumption by Region
  1. 6.1 Global Antitumor API Consumption Estimates and Forecasts by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Antitumor API Consumption by Region (2021-2032)
  3. 6.2.1 Global Antitumor API Consumption by Region: 2021-2026
  4. 6.2.2 Global Antitumor API Forecasted Consumption by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Antitumor API Consumption Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America Antitumor API Consumption by Country (2021-2032)
  8. 6.3.3 United States
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe Antitumor API Consumption Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe Antitumor API Consumption by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Russia
  19. 6.4.8 Spain
  20. 6.4.9 Netherlands
  21. 6.4.10 Switzerland
  22. 6.4.11 Sweden
  23. 6.4.12 Poland
  24. 6.5 Asia Pacific
  25. 6.5.1 Asia Pacific Antitumor API Consumption Growth Rate by Country: 2021 VS 2025 VS 2032
  26. 6.5.2 Asia Pacific Antitumor API Consumption by Country (2021-2032)
  27. 6.5.3 China
  28. 6.5.4 Japan
  29. 6.5.5 South Korea
  30. 6.5.6 India
  31. 6.5.7 Australia
  32. 6.5.8 Taiwan
  33. 6.5.9 Southeast Asia
  34. 6.6 South America, Middle East & Africa
  35. 6.6.1 South America, Middle East & Africa Antitumor API Consumption Growth Rate by Country: 2021 VS 2025 VS 2032
  36. 6.6.2 South America, Middle East & Africa Antitumor API Consumption by Country (2021-2032)
  37. 6.6.3 Brazil
  38. 6.6.4 Argentina
  39. 6.6.5 Chile
  40. 6.6.6 Turkey
  41. 6.6.7 GCC Countries
7 Segment by Type
  1. 7.1 Global Antitumor API Production by Type (2021-2032)
  2. 7.1.1 Global Antitumor API Production by Type (2021-2032) & (kg)
  3. 7.1.2 Global Antitumor API Production Market Share by Type (2021-2032)
  4. 7.2 Global Antitumor API Production Value by Type (2021-2032)
  5. 7.2.1 Global Antitumor API Production Value by Type (2021-2032) & (US$ Million)
  6. 7.2.2 Global Antitumor API Production Value Market Share by Type (2021-2032)
  7. 7.3 Global Antitumor API Price by Type (2021-2032)
8 Segment by Application
  1. 8.1 Global Antitumor API Production by Application (2021-2032)
  2. 8.1.1 Global Antitumor API Production by Application (2021-2032) & (kg)
  3. 8.1.2 Global Antitumor API Production Market Share by Application (2021-2032)
  4. 8.2 Global Antitumor API Production Value by Application (2021-2032)
  5. 8.2.1 Global Antitumor API Production Value by Application (2021-2032) & (US$ Million)
  6. 8.2.2 Global Antitumor API Production Value Market Share by Application (2021-2032)
  7. 8.3 Global Antitumor API Price by Application (2021-2032)
9 Value Chain and Sales Channels Analysis of the Market
  1. 9.1 Antitumor API Value Chain Analysis
  2. 9.1.1 Antitumor API Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Antitumor API Production Mode & Process
  5. 9.2 Antitumor API Sales Channels Analysis
  6. 9.2.1 Direct Comparison with Distribution Share
  7. 9.2.2 Antitumor API Distributors
  8. 9.2.3 Antitumor API Customers
10 Global Antitumor API Analyzing Market Dynamics
  1. 10.1 Antitumor API Industry Trends
  2. 10.2 Antitumor API Industry Drivers
  3. 10.3 Antitumor API Industry Opportunities and Challenges
  4. 10.4 Antitumor API Industry Restraints
11 Report Conclusion
    12 Disclaimer

      GET THE RESEARCH

      Choose your license.

      Choose who needs access.
      All options are for this report and research series.

      Compare access permissions.

      Single User License
      One named user. Individual access.
      Multi User License
      Up to 5 users in the same department.
      Enterprise License
      Organization-wide access within the agreed license.

      Access applies to the purchased edition. Later editions are separate purchases.

      License options
      $2,950USD
      Buy now

      PDF by email within 3–5 working days after payment confirmation.

      Talk to an analyst
      APO Research, Inc.
      Talk to an analyst